Quiz

Article

Clinician Quiz: Hepatitis C Treatment Recommendation Updates

Digital illustration of a clinician (hepatologist) standing next to a liver. | Credit: Pixabay (Mohamed_hassan)

Credit: Pixabay (Mohamed_hassan)

Thanks to advances in technology and pharmacotherapy, the diagnosis and management of hepatitis C virus has evolved greatly in recent years.

In 2023, the American Association for the Study of Liver Diseases partnered with the Infectious Diseases Society of America to develop a focused update to guidance published in 2020. An 18-page document citing more than 160 references, the focused update spotlights major changes related to screening, organ transplant, and expanded treatment options for children and adolescents.

Test your knowledge of these updates in the quiz below:

What are the recommended DAA regimens for HCV treatment-naive adults without cirrhosis according to the simplified treatment approach?


References:

  1. Bhattacharya D, Aronsohn A, Price J, Lo Re V; AASLD-IDSA HCV Guidance Panel . Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin Infect Dis. Published online May 25, 2023. doi:10.1093/cid/ciad319

Editors' note: Artificial intelligence aided in the creation of this content.

Related Videos
Jennifer Lai Yee, MD, PhD, MPH: Honing in on Sparsentan’s Benefit in Genetic FSGS
Highlighting Recent Therapies for Dermatologists, with James Del Rosso, DO
Ladan Zand, MD: Obinutuzumab Promising Option for Refractory, Primary FSGS
Rahul N. Khurana, MD: Phase 1 Results on Vamikibart for Uveitic Macular Edema | Image Credit: Northern California Retina Vitreous Associates
Sunir J. Garg, MD: | Image Credit: Wills Eye Hospital
James Del Rosso, DO: Discussing What’s New in the Medicine Chest for Dermatologists
What to Look Forward To at the Fall Clinical Dermatology Conference, with Raj Chovatiya, MD, PhD
Christine N. Kay, MD: Interim Data on ATSN-201 Shows Promise for XLRS | Image Credit: Vitreo Retinal Associates
Arshad Khanani, MD: First Results from Fellow Eye Dosing of RGX-314 in nAMD | Image Credit: Sierra Eye Associates
© 2024 MJH Life Sciences

All rights reserved.